Aclasta 5mg

Aclasta 5 mg is a specific dosage form of zoledronic acid, a bisphosphonate medication used to treat and prevent bone-related disorders. Each dose contains 5 mg of zoledronic acid, which is administered as an intravenous infusion, usually once a year.

Aclasta 5 mg is primarily prescribed for the treatment of osteoporosis in postmenopausal women and men, helping to reduce the risk of fractures by strengthening bones. It is also used to treat Paget’s disease of bone, a condition that causes bones to become weak and deformed. Additionally, Aclasta 5 mg may be used to manage bone complications in certain cancers that have metastasized to the bones.

The infusion typically takes about 15 minutes, and its effects last for an entire year, making it a convenient treatment option for patients who require long-term bone support. Before receiving Aclasta 5 mg, patients should ensure they have adequate levels of calcium and vitamin D, as the medication can lower blood calcium levels. It’s also important to discuss any kidney issues or other health conditions with a healthcare provider, as Aclasta can affect kidney function.